AR070405A1 - Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual - Google Patents
Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visualInfo
- Publication number
- AR070405A1 AR070405A1 ARP090100332A ARP090100332A AR070405A1 AR 070405 A1 AR070405 A1 AR 070405A1 AR P090100332 A ARP090100332 A AR P090100332A AR P090100332 A ARP090100332 A AR P090100332A AR 070405 A1 AR070405 A1 AR 070405A1
- Authority
- AR
- Argentina
- Prior art keywords
- milligrams
- usp
- composition according
- vitamin
- copper
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 208000002780 macular degeneration Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title 1
- 230000000007 visual effect Effects 0.000 title 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 4
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 4
- 239000006014 omega-3 oil Substances 0.000 abstract 4
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 abstract 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 abstract 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 abstract 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 abstract 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract 3
- 235000010930 zeaxanthin Nutrition 0.000 abstract 3
- 239000001775 zeaxanthin Substances 0.000 abstract 3
- 229940043269 zeaxanthin Drugs 0.000 abstract 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- 229930003268 Vitamin C Natural products 0.000 abstract 2
- 229930003427 Vitamin E Natural products 0.000 abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 235000015872 dietary supplement Nutrition 0.000 abstract 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 2
- 235000012680 lutein Nutrition 0.000 abstract 2
- 229960005375 lutein Drugs 0.000 abstract 2
- 239000001656 lutein Substances 0.000 abstract 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 235000019154 vitamin C Nutrition 0.000 abstract 2
- 239000011718 vitamin C Substances 0.000 abstract 2
- 235000019165 vitamin E Nutrition 0.000 abstract 2
- 229940046009 vitamin E Drugs 0.000 abstract 2
- 239000011709 vitamin E Substances 0.000 abstract 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 abstract 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 abstract 1
- 239000005751 Copper oxide Substances 0.000 abstract 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 abstract 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 abstract 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229940106189 ceramide Drugs 0.000 abstract 1
- 150000001783 ceramides Chemical class 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 229940116318 copper carbonate Drugs 0.000 abstract 1
- 229940108925 copper gluconate Drugs 0.000 abstract 1
- 229910000431 copper oxide Inorganic materials 0.000 abstract 1
- 229910000365 copper sulfate Inorganic materials 0.000 abstract 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 abstract 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 abstract 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 abstract 1
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 235000015110 jellies Nutrition 0.000 abstract 1
- 239000008274 jelly Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 235000012424 soybean oil Nutrition 0.000 abstract 1
- 239000003549 soybean oil Substances 0.000 abstract 1
- 239000004408 titanium dioxide Substances 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 229960000306 zinc gluconate Drugs 0.000 abstract 1
- 235000011478 zinc gluconate Nutrition 0.000 abstract 1
- 239000011670 zinc gluconate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se relaciona con una composicion de suplemento nutricional o dietético que refuerza y promueve la salud de la retina. Reivindicacion 1: Una composicion que comprende una dosis diaria de: aproximadamente de 400 a 600 miligramos de vitamina C, aproximadamente de 350 a 450 UI de vitamina E, aproximadamente de 1 a 20 miligramos de luteína; aproximadamente de 20 a 42 miligramos de zinc; aproximadamente de 1000 a 1800 miligramos de ácidos grasos omega 3, y aproximadamente de 0,8 a 1,35 miligramos de cobre. Reivindicacion 2: La composicion de acuerdo con la reivindicacion 1, la cual comprende zeaxantina, de preferencia en una cantidad de aproximadamente de 1,7 a 2,3 miligramos. Reivindicacion 3: La composicion de acuerdo con la reivindicacion 1, en donde los ácidos grasos omega 3 comprenden ácido docosahexaenoico y ácido eicosapentaenoico. Reivindicacion 9: La composicion de acuerdo con la reivindicacion 8, en donde el recubrimiento es un fosfolípido zwitterionico que incluye pero no se limita a fosfatidil-colina, fosfatidil-serina, fosfatidil-etanolamina, esfingomielina y otras ceramidas, así como varios otros fosfolípidos zwitterionicos. Reivindicacion 12: Una composicion de acuerdo con la reivindicacion 1, la cual es una tableta, cápsula o aglomerado, y comprende: 500 miligramos de vitamina C (Dihidrato de ascorbato de calcio, USP), 400 UI de vitamina E (Acetato de alfa tocoferilo, USP), 40 miligramos de gluconato de zinc, 4,7 miligramos de ?sulfato de cobre o 1,5 miligramos de oxido de cobre, 2,14 miligramos de carbonato de cobre, 8,58 miligramos de gluconato de cobre, 400 miligramos de DHA, 600 miligramos de EPA, 1200 miligramos de total de ácidos grasos Omega 3 (Triglicéridos de ácidos grasos Omega-3, Farmacopea Europea), 10 miligramos de luteína (fuente natural FloraGlo al 20 por ciento (que comprende algo de zeaxantina) o pura), 2 miligramos de zeaxantina (origen sintético), comprendiendo opcionalmente los siguientes excipientes para hacer una cubierta: gelatina 175 de bovino joven, glicerina USP 99 por ciento, hojuelas de aceite de soya (hidrogenadas) NF, aceite de soja USP, y dioxido de titanio USP. Reivindicacion 14: El uso de una composicion de acuerdo con cualquiera de las reivindicaciones anteriores, en la preparacion de un medicamento para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad (AMD) y/o la retinopatía diabética (DR).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08151045 | 2008-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070405A1 true AR070405A1 (es) | 2010-04-07 |
Family
ID=39708779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100332A AR070405A1 (es) | 2008-02-04 | 2009-02-02 | Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR070405A1 (es) |
| CL (1) | CL2009000230A1 (es) |
| PE (1) | PE20091462A1 (es) |
| TW (1) | TW201000027A (es) |
| WO (1) | WO2009098186A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1393710B1 (it) * | 2009-04-29 | 2012-05-08 | Graal Srl | Composizioni orobuccali contenenti una miscela di luteina e zeaxantina. |
| RU2589703C2 (ru) | 2011-09-12 | 2016-07-10 | Тасос ГЕОРГИУ | Применение омега жирных кислот для лечения заболевания |
| CN103211216A (zh) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | 一种辅助改善记忆力功能的保健食品及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002320251A1 (en) * | 2001-07-05 | 2003-01-21 | Vital Basics, Inc. | Compositions for improving mental performance |
| US6649195B1 (en) * | 2002-07-11 | 2003-11-18 | Vitacost.Com, Inc. | Eyesight enhanced maintenance composition |
| US7887847B2 (en) * | 2004-05-08 | 2011-02-15 | Paul Jr Edward L | Nutritional supplement for treatment of ocular diseases |
| FR2883182B1 (fr) * | 2005-03-16 | 2008-02-15 | Novartis Ag | Composition de vitamines utiles dans le traitement des maladies oculaires |
| DE202005012984U1 (de) * | 2005-08-17 | 2005-11-24 | W & B Pharmamarken Gmbh | Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen |
| US7829126B2 (en) * | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
| BRPI0620210A2 (pt) * | 2005-12-20 | 2011-11-01 | Alcon Res Ltd | composição e processos para a inibição da progressão da degeneração macular e para promover visão saudável |
| DE202006014588U1 (de) * | 2006-09-20 | 2006-12-14 | Orthomol Pharmazeutische Vertriebs Gmbh | Carotinoide-enthaltendes Produkt |
-
2009
- 2009-02-02 AR ARP090100332A patent/AR070405A1/es unknown
- 2009-02-02 PE PE2009000147A patent/PE20091462A1/es not_active Application Discontinuation
- 2009-02-02 WO PCT/EP2009/051163 patent/WO2009098186A1/en active Application Filing
- 2009-02-03 CL CL2009000230A patent/CL2009000230A1/es unknown
- 2009-02-03 TW TW098103403A patent/TW201000027A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201000027A (en) | 2010-01-01 |
| WO2009098186A1 (en) | 2009-08-13 |
| CL2009000230A1 (es) | 2009-08-14 |
| PE20091462A1 (es) | 2009-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081580A1 (es) | Composicion suplementaria nutricional para el tratamiento enfermedades oculares | |
| CA2738357C (en) | Methods and compositions to promote ocular health | |
| RU2009126740A (ru) | Композиция питательной добавки, предназначенная для лечения глазных болезней | |
| WO2005110375A8 (en) | Nutritional supplement for treatment of ocular diseases | |
| GB2459809A (en) | Fatty acid formulations and methods of use thereof | |
| ES2606392T3 (es) | Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas | |
| EP3738586A1 (en) | Enteric soft capsules comprising polyunsaturated fatty acids | |
| JPWO2005061684A1 (ja) | 油脂組成物 | |
| PH12018500036A1 (en) | Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid | |
| BR112014005546A2 (pt) | ácidos graxos ômega para tratamento de doenças | |
| WO2012067224A1 (ja) | 角膜上皮障害及び／又は結膜上皮障害の治療又は予防剤 | |
| JP2008533075A (ja) | ビタミン混合物 | |
| WO2011137160A3 (en) | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans | |
| AR070405A1 (es) | Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual | |
| RS52735B (en) | APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS | |
| CA2681514C (en) | Use of a masked or coated copper salt for the treatment of macular degeneration | |
| Trinidad et al. | Importance of the Nutrition with Antioxidants in the Treatment of Cancer and Others Damages | |
| WO2019004969A3 (en) | USE OF A VEGETABLE FORMULATION CONTAINING GRANADO OIL OIL AS AN AUXILIARY AGENT IN THE REDUCTION OF "TRIGLYCERID" BLOOD LIPIDS | |
| EP4090174A1 (en) | A nutraceutical formulation | |
| WO2021028737A1 (es) | Composición lipídica que comprende antioxidantes y polifenoles naturales como alternativa no farmacológica para el tratamiento y la prevención de nafld | |
| PL239957B1 (pl) | Emulsja typu olej w wodzie do zastosowania w kroplach do oczu jako nośnik dla okulistycznych substancji leczniczych rozpuszczalnych w olejach | |
| EP1974733A1 (en) | Use of a masked or coated copper salt for the treatment of macular degeneration | |
| WO2017069631A1 (en) | Method for improving equilibrioception in healthy individuals and nutritional composition | |
| Gilca et al. | Current and Relevant Publications on Vitamins, Carotenoids and Other Health Ingredients Update June 2008 | |
| Crawford | Another Supplement for CAD Prevention Fails |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |